Octagon Capital Advisors LP Portfolio Holdings

Octagon Capital Advisors LP

  • $307 Million
  • Q3 2025

Octagon Capital Advisors LP has filed its 13F form on November 14, 2025 for Q3 2025 where it was disclosed a total value porftolio of $307 Million distributed in 27 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Gossamer Bio, Inc. with a value of $44.8M, Cogent Biosciences, Inc. with a value of $41.3M, Ocular Therapeutix, Inc with a value of $30.7M, Merus N.V. with a value of $29M, and Taysha Gene Therapies, Inc. with a value of $28.6M.

Examining the 13F form we can see an increase of $43.4M in the current position value, from $263M to 307M.

Octagon Capital Advisors LP is based out at New York, NY

Below you can find more details about Octagon Capital Advisors LP portfolio as well as his latest detailed transactions.

Portfolio value $307 Million
Healthcare: $307 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$255M
$44.8 Million 14.61% of portfolio
17,050,000
Q3 2025 Reduced 7.08%
$2.21B
$41.3 Million 13.45% of portfolio
2,874,111
Q3 2025 Added 4.02%
$875M
$30.7 Million 10.0% of portfolio
2,624,000
Q3 2025 Added 8.21%
$4.4B
$29 Million 9.45% of portfolio
308,000
Q3 2025 Reduced 20.82%
$204M
$28.6 Million 9.31% of portfolio
9,067,500
Q3 2025 Reduced 27.99%
$661M
$25.2 Million 8.2% of portfolio
2,815,000
Q3 2025 Reduced 23.34%
$2.23B
$20.4 Million 6.66% of portfolio
903,500
Q2 2025 Reduced 56.85%
$3.55B
$20.4 Million 6.64% of portfolio
360,000
Q3 2025 Added 35.34%
$2.6B
$20.1 Million 6.56% of portfolio
830,000
Q3 2025 Reduced 19.42%
$795M
$18 Million 5.88% of portfolio
722,595
Q3 2025 Added 7.43%
$328M
$15.4 Million 5.01% of portfolio
1,273,333
Q2 2025 Reduced 7.06%
$1.06B
$9.74 Million 3.18% of portfolio
2,633,334
Q3 2025 Reduced 65.76%
$112M
$3.23 Million 1.05% of portfolio
700,000
Q3 2025 New
-
$0 0.0% of portfolio
-
Q3 2025 Reduced 32.44%
Structure Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2025 New
Abivax Sa
-
$0 0.0% of portfolio
-
Q3 2025 Added 4.58%
Mind Medicine Mindmed Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 29.42%
Maze Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 62.04%
Dianthus Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2025 Added 3.2%
Dbv Technologies S A
-
$0 0.0% of portfolio
-
Q2 2025 New
Corbus Pharmaceuticals Hldgs
-
$0 0.0% of portfolio
-
Q1 2025 Reduced 68.61%
Cidara Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2025 New
Bridgebio Oncology Therapeut
-
$0 0.0% of portfolio
-
Q3 2025 New
Arrivent Biopharma Inc
-
$0 0.0% of portfolio
-
Q3 2025 Added 1.28%
Unicycive Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 New

Summary

  • Portfolio
  • No. of Stocks 27
  • Current Value $307 Million
  • Prior Value $263 Million
  • Filing
  • Period Q3 2025
  • Filing Date November 14, 2025
  • Form Type 13F-HR
  • Activity in Q3 2025
  • New Purchases 4 stocks
  • Additional Purchases 7 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 8 stocks
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email